HTT EXON1

# Research Brief: HTT Exon 1 Q23 Variant ## Pathogenic Mechanisms The HTT exon 1 Q23 variant represents a polyglutamine expansion in the huntingtin protein associated with Huntington's disease pathology. Literature findings establish that pathogenicity involves complex molecular mechanisms centered on the N17 domain, particularly leucine 7, which mediates mitochondrial dysfunction. The polyglutamine expansion creates both gain-of-function toxicity through protein aggregation and loss-of-function effects through altered chromatin architecture. The variant's molecular functions include critical cytoskeletal interactions through beta-tubulin binding and motor protein complex formation via dynactin and dynein intermediate chain binding. These interactions are essential for establishment of mitotic spindle orientation and central nervous system development, suggesting that disruption of these processes contributes to neurodegeneration. The pathology involves tissue-specific molecular signatures, with protein aggregation driving progressive dysfunction in affected neural tissues through mechanisms that extend beyond simple protein misfolding to include disruption of fundamental cellular processes including apoptotic signaling. ## Clinical Significance The Q23 polyglutamine expansion in HTT exon 1 represents an intermediate-length repeat that falls within the pathogenic range for Huntington's disease, though specific population frequency data and formal pathogenicity classifications were not available in the current dataset. The variant's clinical impact stems from interference with huntingtin's normal cellular functions, including its roles in microtubule-based transport, ubiquitination processes (interactions with UBE2K, RNF20), and membrane trafficking (ARFGAP3 interaction). The disruption of these protein-protein interactions, particularly with ZDHHC17 and UBAC1, likely contributes to the neurodegenerative phenotype through cumulative cellular dysfunction affecting multiple pathways essential for neuronal health and survival. ## Therapeutic Landscape A promising aggregation hotspot has been identified at residues 1497-1501 with a high aggregation propensity score of 0.83, providing a rational target for therapeutic intervention. The candidate peptide CP-HTT-001 has been computationally designed to specifically target this high-scoring aggregation region, offering potential to disrupt pathological protein-protein interactions and reduce aggregate formation. The therapeutic strategy encompasses multiple approaches including targeting N17 domain-mediated mitochondrial dysfunction and modulating chromatin architecture changes. The cross-variant synthesis suggests a multi-modal therapeutic landscape, though specific peptide inhibitors with published PMID references were not detailed in the available data. ## Research Directions Critical knowledge gaps remain in understanding tissue-specific vulnerability patterns and the relative contributions of gain- versus loss-of-function mechanisms in different neural populations. Priority research directions should include: (1) validation of CP-HTT-001 peptide efficacy in cellular and animal models; (2) detailed characterization of how the Q23 expansion specifically affects interactions with ZDHHC17, UBAC1, and other critical binding partners; (3) investigation of whether targeting the 1497-1501 aggregation hotspot can preserve normal huntingtin functions while reducing toxicity; and (4) elucidation of the molecular basis for tissue-specific pathology to enable targeted therapeutic strategies for vulnerable brain regions.